KYTX Kyverna Therapeutics, Inc. Common Stock
XNAS
5.27
Delayed
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
KYTX
$5.27
—
Key stats
$5.27
Pre-market
$5.20
-1.33%
- 52-Week Range
- $5.18 – $13.67
- YTD
- -39.91%
- IV Rank (30D)
- 18.54
- Straddle Price
- $2.83
- P/C Vol Ratio
- 1.09
- Market Cap
- $0.3B
- Open
- $5.35
- Day Range
- $5.18 – $5.41
- Volume
- 810,112
- Prev Close
- $5.39
Fair Value
+50.0% vs price
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 4.96% |
| Beta vs SPY | 1.50 |
| Cost of Equity (CAPM) | 13.22% (VRP-adj) |
| WACC | 12.74% |
| Volatility Risk Premium | +152.3pp (IV − HV30), ERP adj +50bps |
| Effective Tax Rate | 21.0% |
| Rev. Growth (YoY, DCF input) | +3.0% |
| DCF Horizon | 5 years explicit + fade |
| Forward Tilt (NTM/TTM) | ×1.03 (applied to P/E, EV/EBITDA, P/S) |
| Free Cash Flow (TTM) | $-0.2B |
| Return on Equity (TTM) | -92.2% |
| Book / Price | 59.3% — banking bias active (P/B is primary) |
| Debt / Equity | 0.15 |
| Quality Score | 1/6 — cyclical/struggling (5y DCF) |
| SMA 50 | $7.13 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $6.05 |
| Bollinger Width / SMA20 | 443.6% (drives anchor stability) |
| Net Debt | $-0.0B |
| Market Cap | $0B |
Peers used for multiples: ABEO, CLDX, DCTH
(filtered from 8 ETF-co-members; sector bias active)
Blended Fair Value
$10.03
Deviation
+50.0%
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | n/a | 0% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | n/a | 0% | |
| Peer EV/EBITDA | n/a | 0% | |
| Peer P/B | $10.03 | 100% | median 3.2× · 3 peers |
| Peer P/S | n/a | 0% | median 9.9× · 3 peers |
| Market Anchor (SMA50) | $7.13 | 0% | stability 0% (BB-width) |
| Options Expected (B-L 30d) | n/a | 0% |
As of 2026-10-27 · updated
Related
About
- Industry (SIC)
- BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) (2836) · industry map
- Exchange
- XNAS
- Market Cap
- $0.3B
- Employees
- 149
- List Date
- 2024-02-08
- CIK
- 0001994702
- Next Earnings
- 2026-11-11 (After-Close)
- EPS Forecast
- ($0.68) (4 est.)
- Headquarters
- Emeryville, CA
- Homepage
- https://www.kyvernatx.com
Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '24 | '25 | '26 | Avg |
|---|---|---|---|---|
| Jan | -- | -17.35% | -8.67% | -13.01% |
| Feb | -9.43% | -8.39% | -1.44% | -6.42% |
| Mar | -10.49% | -25.48% | 1.41% | -11.52% |
| Apr | -32.77% | 16.67% | 0.34% | -5.25% |
| May | -24.56% | 14.86% | -3.95% | -4.55% |
| Jun | -42.62% | 15.85% | 8.39% | -6.13% |
| Jul | 10.88% | 28.88% | -14.17% | 8.53% |
| Aug | 2.29% | 7.85% | 12.85% | 7.66% |
| Sep | -33.51% | 67.13% | -18.56% | 5.02% |
| Oct | 1.06% | 16.75% | -19.17%* | -0.45% |
| Nov | 18.00% | 11.48% | -- | 14.74% |
| Dec | -42.37% | 39.67% | -- | -1.35% |
| Total | -87.77% | 269.91% | -39.20% | 47.65% |
* Only 3 year(s) of data available.
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $6.05
SMA 50: $7.13
SMA 200: $8.15
Current: $5.27
EMA 12: $5.80
EMA 26: $6.24
MACD: -0.4367 | Signal: -0.0156
BEARISH
ADX (14): 17.36
RANGE
+DI: 15.95
−DI: 27.39
Momentum Oscillators
RSI (14): 30.21
NEUTRAL
Stoch %K: 7.09
Stoch %D: 13.53
Williams %R: -93.57
Volume & Volatility
BB Upper: $6.86
BB Lower: $5.24
NEUTRAL
OBV: 29,467,753
Vol SMA 20: 848,655
Vol ROC: 94.19%
ATR: $0.38
True Range: $0.23
HV 20: 54.0%
HV 30: 53.7%
HV 60: 56.9%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-10-28T00:00:00 – 2026-10-26T00:00:00
AI Analysis
LLM Stock Analysis Report
Executive Summary Overall assessment: BEARISH (confidence level: 6/10) Key drivers: Recent bearish news sentiment, increasing volatility, and high beta Primary risks: High volatility, market sentiment turning negative, and earnings miss expectations Recent news sentiment impact: Negative headlines have contributed to the current bearish trend
Technical Analysis Trend Direction:
- Short-term (1-4 weeks): DOWNWARD TREND
- Medium-term (1-3 months): NEUTRAL/ Sideways trend
- Long-term (3-12 months): UPTREND
Support/Resistance Levels:
- Key price levels: $7.55 (SMA 20), $8.03 (Upper Bollinger Band)
Momentum Signals:
- RSI interpretation: Neutral, around 50.78 (no clear buy/sell signal)
- MACD signal: Bearish crossover
- Bollinger Bands position: Squeeze, indicating potential breakout/breakdown
Volume Analysis:
- Volume SMA 20: 928930.25 (neutral volume trend)
- On-Balance Volume (OBV): 39513710.48 ( bearish OBV trend)
News & Sentiment Analysis Recent Headlines Summary:
- Positive headline about clinical trials
- Negative headline comparing Kyverna Therapeutics and Vertex Pharmaceuticals
- Positive headline announcing investor conference presentation
- Positive headline presenting registrational trial primary analysis
- Positive headline appointing new board members
- Neutral headline discussing M&A trends
Sentiment Assessment: NEGATIVE (due to recent bearish news headlines)
Catalyst Identification:
- Upcoming earnings release (no specific date available)
- Investor conference presentation (already announced)
- Regulatory updates (none recently announced)
Risk & Volatility Assessment Beta Interpretation: High risk relative to market (beta >1.5)
Volatility Regime: Current volatility is higher than historical levels
Options Market Signals:
- IV rank: 41.1% (medium volatility)
- Put/call ratios: Neutral sentiment
- Unusual activity: None notable
Downside Protection:
- Support levels: $7.55 (SMA 20) and $7.07 (Lower Bollinger Band)
Market Context & Positioning Sector Performance: Kyverna Therapeutics is underperforming its sector
Institutional Activity: Neutral institutional sentiment, no clear buying or selling signal
Correlation Analysis:
- R-squared interpretation: Weak correlation between stock price and market index
Relative Valuation: The stock is trading within a range, with some upward pressure from recent positive headlines
Key Levels & Action Items Critical Price Levels:
- Support: $7.55 (SMA 20) and $7.07 (Lower Bollinger Band)
- Resistance: $8.03 (Upper Bollinger Band)
Breakout/Breakdown Levels:
- Potential breakout above $8.03
- Potential breakdown below $7.55
Time-Sensitive Catalysts:
- Upcoming earnings release (no specific date available)
- Investor conference presentation (already announced)
Risk Management:
- Stop-loss levels: $6.50 and $5.80 (based on recent lows and volatility considerations)
- Position sizing: Consider reducing position size due to high risk and volatility
Please note that this report is for informational purposes only and should not be taken as investment advice.
Generated
News
All KYTX news →
Earnings History
12 of 12 under expected move
Avg Expected Move
41.50%
Avg Actual Move
5.72%
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2024-03-26 | After-Close | 40.23% | 3.02% | 0.08x | Within |
| 2024-05-14 | After-Close | 36.77% | 2.39% | 0.06x | Within |
| 2024-08-12 | After-Close | 70.44% | 7.20% | 0.10x | Within |
| 2024-11-13 | After-Close | 14.82% | 5.14% | 0.35x | Within |
| 2025-03-27 | After-Close | 65.82% | 15.07% | 0.23x | Within |
| 2025-05-13 | After-Close | 32.33% | 7.33% | 0.23x | Within |
| 2025-08-12 | After-Close | 135.76% | 14.90% | 0.11x | Within |
| 2025-11-12 | Pre-Market | 22.86% | 4.71% | 0.21x | Within |
| 2026-01-12 | Pre-Market | 9.62% | 1.08% | 0.11x | Within |
| 2026-03-26 | Pre-Market | 37.17% | 2.03% | 0.05x | Within |
| 2026-05-12 | After-Close | 7.58% | 5.38% | 0.71x | Within |
| 2026-08-11 | After-Close | 24.63% | 0.37% | 0.02x | Within |
Earnings calendar: this week’s reports with expected vs actual moves →
KYTX Options Activity & IV Rank
KYTX IV rank history, 52-week IV rank and IV percentile →
Volatility Metrics
Current IV: 103.3%
7-DTE IV: —
Expected Move: $2.83
7-DTE Move: $2.83
Days to Exp: 25 (2026-11-20)
Options Flow
Call Volume: 412
Put Volume: 450
P/C Volume: 1.092
NEUTRAL
Call OI: 665
Put OI: 148
P/C OI: 0.223
Total OI: 813
ATM Options Pricing
ATM Call: $2.50
ATM Put: $0.33
Call %: 47.4%
Put %: 6.2%
Chain Summary
Chain Volume: 1,686
Chain OI: 10,291
Last Updated: 10/26/2026
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Dealer Positioning
TYPICAL γ
Estimated net dealer gamma is at the 42nd percentile of this name's own daily history, within its typical range. This describes current positioning; it is not a forecast or a trading signal.
Gamma percentile
42%
vs own history
GEX tilt
+0.56
OI-weighted, today
Vanna tilt
-1.00
δ-sensitivity to IV
Charm tilt
+0.96
δ-decay vs time
Vanna tilt -1.00: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably if implied volatility changed.
Charm tilt +0.96: the estimated dealer exposure leans positive, so the modeled hedge would shift noticeably as time passes and options approach expiry.
? What is this?
· 3 ATM contracts, 1k total OI
Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.
Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.
Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.
This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
as of Oct 26 · No data
30 DTE / 10d
—
—
pts
EXTREME
as of Oct 26 · ATM 275.3% / Wing —
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Enter a ticker to render the implied volatility surface.
Volatility Smile
Enter a ticker to render the implied volatility smile.
IV Rank (7 DTE)
IV Rank (30 DTE)18.5LowOct 26
Straddle Price (30 DTE)$2.83Oct 26
Beta Analysis
Risk Metrics
Beta: 2.1445
Alpha: -23.13%
Correlation: 0.3117
R-Squared: 9.7%
Stock Volatility: 87.7%
Market Volatility: 12.7%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
High volatility - stock moves more than market
High volatility - stock moves more than market
Beta & Alpha Over Time
Notable investors who own KYTX
3 of 37 tracked investors
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Millennium Management Hedge fund Izzy Englander | $5.7M | #1971 of 3716 | -36.4% | 13F | |
| Renaissance Technologies Hedge fund Jim Simons | $3.0M | #1745 of 3138 | -9.1% | 13F | |
| Citadel Hedge fund Ken Griffin | $1.3M | #3376 of 6285 | +154.0% | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
KYTX Institutional Ownership (13F)
Latest filings — 2026-09-30
? 13F Guide
Diluted shares outstanding: 52,982,531 (as of 2026-06-30)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
4 filers$1.73M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Citadel Advisors LLC Custodian | $1.10M | 63.59% | 2026-06-30 |
| 2 | Susquehanna International Group, LLP Custodian | $314.52K | 18.21% | 2026-06-30 |
| 3 | Jane Street Group, LLC Custodian | $176.42K | 10.21% | 2026-06-30 |
| 4 | Simplex Trading, LLC Custodian | $138.10K | 7.99% | 2026-06-30 |
4 filers$1.20M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Susquehanna International Group, LLP Custodian | $492.72K | 41.15% | 2026-06-30 |
| 2 | Citadel Advisors LLC Custodian | $454.41K | 37.95% | 2026-06-30 |
| 3 | Jane Street Group, LLC Custodian | $245.03K | 20.46% | 2026-06-30 |
| 4 | Simplex Trading, LLC Custodian | $5.35K | 0.45% | 2026-06-30 |
KYTX Insider Trading (Form 4)
Latest: 2026-05-29Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-05-29 | Ian T Clark | Director | Award (A) | +5,093 | — | EDGAR | |
| 2026-05-29 | Beth C Seidenberg | Director | Award (A) | +5,093 | — | EDGAR | |
| 2026-05-29 | Christi Shaw | Executive Chairperson | Tax (F) | −4,194 | $8.59 | -$36.0K | EDGAR |
| 2026-05-29 | Mert Aktar | Director | Award (A) | +5,093 | — | EDGAR | |
| 2026-05-29 | Fred E Cohen | Director | Award (A) | +5,093 | — | EDGAR | |
| 2026-05-20 | Gregory S. Martini | Chief Financial Officer | Grant (A) | +325,000 opt | — | EDGAR | |
| 2026-05-06 | Nadia Dac | Chief Commercial Officer | Grant (A) | +300,000 opt | — | EDGAR | |
| 2026-03-17 | Warner Weston Biddle | Chief Executive Officer | Award (A) | +58,000 | — | EDGAR | |
| 2026-03-17 | Marc Grasso | Chief Financial Officer | Award (A) | +10,000 | — | EDGAR | |
| 2026-03-17 | Naji Gehchan | See Remarks | Award (A) | +18,000 | — | EDGAR | |
| 2026-03-04 | Andrew Craig Miller | Director | Award (A) | +11,006 | — | EDGAR | |
| 2026-02-26 | Sravan Kumar Emany | Director | Award (A) | +11,006 | — | EDGAR | |
| 2026-02-11 | Mayobanex Pujols | Chief Technology Officer | Grant (A) | +300,000 opt | — | EDGAR | |
| 2026-01-14 | Christi Shaw | Executive Chairperson | Award (A) | +54,301 | — | EDGAR | |
| 2025-12-22 | Westlake BioPartners GP I, LLC | 10%+ Owner | Buy (P) | +533,332 | $7.50 | $4.00M | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
KYTX Insider Holdings
14 insiders · @ $5.27
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Fred E Cohen | Director | 4,545,651 | $23.96M | $0 | 3 | 2026-05-29 |
| 2 | Beth C Seidenberg | Director | 3,809,667 | $20.08M | $1000.0K | 4 | 2026-05-29 |
| 3 | Westlake BioPartners GP I, LLC | 10%+ Owner | 3,787,940 | $19.96M | $4.00M | 1 | 2025-12-22 |
| 4 | Christi Shaw | Executive Chairperson | 66,741 | $351.7K | $0 | 5 | 2026-05-29 |
| 5 | Warner Weston Biddle | Chief Executive Officer | 58,000 | $305.7K | $0 | 3 | 2026-03-17 |
| 6 | Ryan Alexander Jones | Chief Financial Officer | 55,950 | $294.9K | $0 | 2 | 2025-04-15 |
| 7 | Karen Marie Walker | Chief Technology Officer | 46,634 | $245.8K | -$292.8K | 3 | 2025-12-17 |
| 8 | Ian T Clark | Director | 21,727 | $114.5K | $0 | 2 | 2026-05-29 |
| 9 | Mert Aktar | Director | 21,727 | $114.5K | $0 | 3 | 2026-05-29 |
| 10 | Naji Gehchan | See Remarks | 18,000 | $94.9K | $0 | 2 | 2026-03-17 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
KYTX Board & Officers
As of SEC filings through May 29, 2026Directors 8
- Beth C Seidenberg · since Feb 7, 2024
- Fred E Cohen · since Feb 7, 2024
- Ian T Clark · since Feb 7, 2024
- Christi Shaw · since Sep 16, 2024
- Warner Weston Biddle · since Sep 16, 2024
- Mert Aktar · since Oct 21, 2024
- Andrew Craig Miller · since Feb 24, 2026
- Sravan Kumar Emany · since Feb 24, 2026
Officers 6
- Warner Weston Biddle · Chief Executive Officer · since Sep 16, 2024
- Gregory S. Martini · Chief Financial Officer · since May 18, 2026
- Naji Gehchan · Chief Medical & Development Officer · since Jan 22, 2025
- Mayobanex Pujols · Chief Technology Officer · since Feb 9, 2026
- Nadia Dac · Chief Commercial Officer · since May 4, 2026
- Christi Shaw · Executive Chairperson · listed since Jan 2026
10% owners 1
- Fred E Cohen · since Feb 7, 2024
Changes in the last 10 years (66)
| May 18, 2026 | Gregory S. Martini became Chief Financial Officer |
| May 14, 2026 | The company announced the departure of Marc Grasso as Chief Financial Officer in an SEC filing |
| May 4, 2026 | Nadia Dac became Chief Commercial Officer |
| Feb 24, 2026 | Sravan Kumar Emany became a director |
| Feb 24, 2026 | Andrew Craig Miller became a director |
| Feb 23, 2026 | The company announced the departure of Daniel K Spiegelman from the board in an SEC filing |
| Feb 9, 2026 | Mayobanex Pujols became Chief Technology Officer |
| Jan 29, 2026 | The company announced the departure of Karen Marie Walker as Chief Technology Officer in an SEC filing |
| Jan 14, 2026 | Christi Shaw first listed as Executive Chairperson in an SEC filing |
| Dec 22, 2025 | Westlake BioPartners Opportunity GP I, LLC reported in an SEC filing no longer being a 10% owner |
| Dec 22, 2025 | Westlake BioPartners Opportunity Fund I, L.P. reported in an SEC filing no longer being a 10% owner |
| Dec 22, 2025 | Westlake BioPartners GP I, LLC reported in an SEC filing no longer being a 10% owner |
| Dec 22, 2025 | Westlake BioPartners Fund I, L.P. reported in an SEC filing no longer being a 10% owner |
| Dec 22, 2025 | Beth C Seidenberg no longer listed as a 10% owner in SEC filings |
| Jun 30, 2025 | The company announced the departure of Ryan Alexander Jones as Chief Financial Officer in an SEC filing |
| Jun 30, 2025 | Marc Grasso became Chief Financial Officer |
| Jan 22, 2025 | Naji Gehchan became Chief Medical & Development Officer |
| Nov 8, 2024 | The company announced the departure of James Bum Chung as Chief Medical Officer in an SEC filing |
| Oct 21, 2024 | Mert Aktar became a director |
| Sep 16, 2024 | Warner Weston Biddle became a director |
| Sep 16, 2024 | Warner Weston Biddle became Chief Executive Officer |
| Sep 16, 2024 | Christi Shaw became a director |
| Sep 13, 2024 | The company announced the departure of Peter Maag from the board in an SEC filing |
| Sep 13, 2024 | The company announced the departure of Peter Maag as Chief Executive Officer in an SEC filing |
| Sep 13, 2024 | The company announced the departure of Brian L. Kotzin from the board in an SEC filing |
| Feb 14, 2024 | Vida Ventures III-A, L.P. first on file as a 10% owner |
| Feb 14, 2024 | Vida Ventures III, L.P. first on file as a 10% owner |
| Feb 14, 2024 | Vida Ventures GP III, L.L.C. first on file as a 10% owner |
| Feb 14, 2024 | Bain Capital Life Sciences Opportunities III, LP reported in an SEC filing no longer being a 10% owner |
| Feb 14, 2024 | Bain Capital Life Sciences Opportunities III GP, LLC reported in an SEC filing no longer being a 10% owner |
| Feb 14, 2024 | Bain Capital Life Sciences Investors, LLC reported in an SEC filing no longer being a 10% owner |
| Feb 14, 2024 | Bain Capital Life Sciences III General Partner, LLC reported in an SEC filing no longer being a 10% owner |
| Feb 14, 2024 | Bain Capital Life Sciences Fund III, L.P. reported in an SEC filing no longer being a 10% owner |
| Feb 13, 2024 | Gilead Sciences, Inc. reported in an SEC filing no longer being a 10% owner |
| Feb 12, 2024 | Northpond Ventures III, LP reported in an SEC filing no longer being a 10% owner |
| Feb 12, 2024 | Northpond Ventures III GP, LLC reported in an SEC filing no longer being a 10% owner |
| Feb 12, 2024 | Michael P. Rubin reported in an SEC filing no longer being a 10% owner |
| Feb 7, 2024 | Westlake BioPartners Opportunity GP I, LLC became a 10% owner |
| Feb 7, 2024 | Westlake BioPartners Opportunity Fund I, L.P. became a 10% owner |
| Feb 7, 2024 | Westlake BioPartners GP I, LLC became a 10% owner |
| Feb 7, 2024 | Westlake BioPartners Fund I, L.P. became a 10% owner |
| Feb 7, 2024 | Vida Ventures, LLC became a 10% owner |
| Feb 7, 2024 | Stephen Constantine Liapis became a director |
| Feb 7, 2024 | Sean E Harper became a 10% owner |
| Feb 7, 2024 | Ryan Alexander Jones became Chief Financial Officer |
| Feb 7, 2024 | Peter Maag became a director |
| Feb 7, 2024 | Peter Maag became Chief Executive Officer |
| Feb 7, 2024 | Northpond Ventures III, LP became a 10% owner |
| Feb 7, 2024 | Northpond Ventures III GP, LLC became a 10% owner |
| Feb 7, 2024 | Michael P. Rubin became a 10% owner |
| Feb 7, 2024 | Karen Marie Walker became Chief Technology Officer |
| Feb 7, 2024 | James Bum Chung became Chief Medical Officer |
| Feb 7, 2024 | Ian T Clark became a director |
| Feb 7, 2024 | Gilead Sciences, Inc. became a 10% owner |
| Feb 7, 2024 | Fred E Cohen became a director |
| Feb 7, 2024 | Fred E Cohen became a 10% owner |
| Feb 7, 2024 | Dominique Christian Borie became an officer |
| Feb 7, 2024 | Daniel K Spiegelman became a director |
| Feb 7, 2024 | Brian L. Kotzin became a director |
| Feb 7, 2024 | Beth C Seidenberg became a director |
| Feb 7, 2024 | Beth C Seidenberg became a 10% owner |
| Feb 7, 2024 | Bain Capital Life Sciences Opportunities III, LP became a 10% owner |
| Feb 7, 2024 | Bain Capital Life Sciences Opportunities III GP, LLC became a 10% owner |
| Feb 7, 2024 | Bain Capital Life Sciences Investors, LLC became a 10% owner |
| Feb 7, 2024 | Bain Capital Life Sciences III General Partner, LLC became a 10% owner |
| Feb 7, 2024 | Bain Capital Life Sciences Fund III, L.P. became a 10% owner |
Not reported recently (7)
- Vida Ventures, LLC · Last reported as a 10% owner in an SEC filing dated Feb 14, 2024
- Sean E Harper · Last reported as a 10% owner in an SEC filing dated Feb 14, 2024
- Vida Ventures III, L.P. · Last reported as a 10% owner in an SEC filing dated Feb 14, 2024
- Vida Ventures GP III, L.L.C. · Last reported as a 10% owner in an SEC filing dated Feb 14, 2024
- Vida Ventures III-A, L.P. · Last reported as a 10% owner in an SEC filing dated Feb 14, 2024
- Stephen Constantine Liapis · Last reported as a director in an SEC filing dated Feb 8, 2024
- Dominique Christian Borie · Last reported as an officer in an SEC filing dated Feb 7, 2024
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
KYTX Proposed Insider Sales (Form 144)
Latest: 2026-04-17
? Form 144 Guide
Last 30d:
0 filings
· Last 90d:
0 filings
What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.
How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.
10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.
"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.
Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.
| Filed | Filer | Role | Shares | Notice Value | Planned Sale | Broker | Plan | Link |
|---|---|---|---|---|---|---|---|---|
| 2026-04-17 | KAREN WALKER | Officer | 10,000 | $95.3K | 2026-04-17 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-04-14 | KAREN WALKER | Officer | 2,459 | $23.3K | 2026-04-14 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-04-07 | DANIEL SPIEGELMAN | Director | 17,578 | $162.6K | 2026-04-07 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| 2026-03-31 | DANIEL SPIEGELMAN | Director | 16,634 | $140.4K | 2026-03-31 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| 2025-12-15 | KAREN WALKER | Officer | 23,998 | $210.7K | 2025-12-15 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
ETF Holders
39 ETFs hold KYTX
25 shown · $35.94M total exposure · 0.01% AUM-weighted avg weight
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | VTI Vanguard Morningstar Total Stock Market ETF | Vanguard | 0.00% | $10.7M | — | 2026-09-30 |
| 2 | IWM iShares Russell 2000 ETF | iShares (BlackRock) | 0.01% | $5.8M | $74.6B | 2026-10-23 |
| 3 | FESM Fidelity Enhanced Small Cap Core ETF | Fidelity | 0.04% | $2.7M | $6.6B | 2026-10-23 |
| 4 | VXF Vanguard Extended Market ETF | Vanguard | 0.00% | $2.7M | — | 2026-09-30 |
| 5 | IWN iShares Russell 2000 Value ETF | iShares (BlackRock) | 0.01% | $1.9M | $13.9B | 2026-10-23 |
| 6 | VTWO Vanguard Russell 2000 ETF | Vanguard | 0.01% | $1.7M | — | 2026-09-30 |
| 7 | SURI Simplify Propel Opportunities ETF | Nport | 2.11% | $1.6M | — | 2026-06-30 |
| 8 | IBB iShares Biotechnology ETF | iShares (BlackRock) | 0.01% | $1.5M | $10.7B | 2026-10-23 |
| 9 | SCHA Schwab U.S. Small-Cap ETF | Nport | 0.01% | $1.4M | — | 2026-05-31 |
| 10 | DWAS Invesco Dorsey Wright SmallCap Momentum ETF | Nport | 0.34% | $1.4M | — | 2026-05-31 |
| 11 | KOMP State Street® SPDR® S&P Kensho New Economies Composite ETF | SPDR (State Street) | 0.06% | $1.4M | $2.5B | 2026-10-23 |
| 12 | IWC iShares Micro-Cap ETF | iShares (BlackRock) | 0.06% | $684,363 | $1.2B | 2026-10-23 |
| 13 | DFAS Dimensional US Small Cap ETF | Dimensional | 0.00% | $417,450 | — | 2026-10-23 |
| 14 | AVSC Avantis U.S. Small Cap Equity ETF | Avantis | 0.01% | $358,316 | $3.2B | 2026-10-23 |
| 15 | DFAC Dimensional US Core Equity 2 ETF | Dimensional | 0.00% | $275,990 | — | 2026-10-23 |
| 16 | VTWV Vanguard Russell 2000 Value ETF | Vanguard | 0.02% | $239,374 | — | 2026-09-30 |
| 17 | PRFZ Invesco RAFI US 1500 Small-Mid ETF | Nport | 0.01% | $223,752 | — | 2026-07-31 |
| 18 | IWO iShares Russell 2000 Growth ETF | iShares (BlackRock) | 0.00% | $185,583 | $13.7B | 2026-10-23 |
| 19 | DCOR Dimensional US Core Equity 1 ETF | Dimensional | 0.00% | $135,882 | — | 2026-10-23 |
| 20 | SCHB Schwab U.S. Broad Market ETF | Nport | 0.00% | $127,800 | — | 2026-05-31 |
| 21 | DFMC Dimensional US Micro Cap ETF | Dimensional | 0.00% | $112,565 | — | 2026-10-23 |
| 22 | DXUV Dimensional US Vector Equity ETF | Dimensional | 0.00% | $109,498 | — | 2026-10-23 |
| 23 | RSSL Global X Russell 2000 ETF | Global X | 0.01% | $107,571 | — | 2026-10-26 |
| 24 | DFAU Dimensional US Core Equity Market ETF | Dimensional | 0.00% | $69,995 | $13.0B | 2026-10-23 |
| 25 | DFUS Dimensional US Equity Market ETF | Dimensional | 0.00% | $49,135 | $21.7B | 2026-10-23 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Trailing P/E
—
TTM Diluted EPS
$-2.94
TTM Revenue
—
TTM Net Income
$-152.64M
TTM Op. Cash Flow
$-158.75M
Quarterly figures (10 quarters)
| Quarter | Period End | Revenue | Net Income | Diluted EPS | Op. Cash Flow |
|---|---|---|---|---|---|
| Q2 '26 | 2026-06-30 | — | $-38.32M | $-0.63 | $-40.31M |
| Q1 '26 | 2026-03-31 | — | $-39.73M | $-0.66 | $-41.60M |
| Q4 '25 | 2025-12-31 | — | $-37.80M | $-0.79 | $-33.53M |
| Q3 '25 | 2025-09-30 | — | $-36.79M | $-0.85 | $-43.32M |
| Q2 '25 | 2025-06-30 | — | $-42.08M | $-0.97 | $-31.95M |
| Q1 '25 | 2025-03-31 | — | $-44.63M | $-1.03 | $-44.91M |
| Q4 '24 | 2024-12-31 | — | $-37.49M | $-0.88 | $-37.06M |
| Q3 '24 | 2024-09-30 | — | $-34.49M | $-0.80 | $-27.49M |
| Q2 '24 | 2024-06-30 | — | $-28.80M | $-0.67 | $-24.18M |
| Q1 '24 | 2024-03-31 | — | $-26.69M | $-1.12 | $-25.52M |
Q2 2026 • period ending 2026-06-30 • filed 2026-08-11
Valuation
Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.
Price Multiples
- P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
- P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
- P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
- EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
- EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
- ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
- ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
- Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
- FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
- Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
- Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
- Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
- Multiples expanding while earnings are flat = sentiment-driven rally.
- Multiples compressing while earnings grow = value coming from fundamentals.
P/E
—
P/B
1.69
P/S
—
EV/EBITDA
—
EV/Sales
—
ROE
-92.2%
ROA
-69.4%
Div Yield
0.00%
FCF Yield
-56.86%
Debt/Equity
0.15
Current Ratio
—
Market Cap
$279.22M
as of 2026-10-26
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
9.62M
SI % of Float
26.15%
Days to Cover
8.85
Short Vol Ratio
65.4%
Free Float
36.78M
Float %
60.5%
Short interest 2026-09-30 • Short volume 2026-10-26 • Float 2026-05-27